Lack of association between the levels of the low-density lipoprotein receptor-related protein (LRP) and either Alzheimer dementia or LRP exon 3 genotype

J Neuropathol Exp Neurol. 2003 Oct;62(10):999-1005. doi: 10.1093/jnen/62.10.999.


The low-density lipoprotein receptor-related protein (LRP), which interacts with the Alzheimer disease (AD) beta-amyloid precursor protein (APP), represents an important pathway in AD pathology. LRP-mediated receptor pathways appear to regulate both the production and the clearance of amyloid beta-protein (Abeta), a principal neuropathological product in AD. Several conflicting studies have examined levels of LRP in AD brains, as well as the relationship between the LRP exon 3 (C766T) polymorphism and LRP levels and/or disease susceptibility. In order to further investigate the role of LRP in AD, we examined well-characterized brain samples collected from subjects with varying degrees of cognitive impairment for LRP protein expression levels as well as for the presence of the LRP exon 3 polymorphism. We found no correlation between LRP levels and either presence of the disease or cognitive decline. In addition, we found no correlation between the LRP exon 3 polymorphism and either AD or LRP levels.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alzheimer Disease / metabolism*
  • Blotting, Western
  • Brain / metabolism*
  • Brain Chemistry*
  • Cohort Studies
  • Cysteine / genetics
  • Exons*
  • Genotype*
  • Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism
  • Humans
  • Low Density Lipoprotein Receptor-Related Protein-1 / genetics
  • Low Density Lipoprotein Receptor-Related Protein-1 / metabolism*
  • Polymorphism, Genetic
  • Threonine / genetics


  • Low Density Lipoprotein Receptor-Related Protein-1
  • Threonine
  • Glyceraldehyde-3-Phosphate Dehydrogenases
  • Cysteine